Delix Therapeutics

Watch as Delix Therapeutics' Chief Medical Officer, Aaron Koenig MD, presents?compelling Phase 1 trial results for DLX-001, a novel #neuroplastogen, in a video series by the Psychiatric Times. These groundbreaking findings highlight DLX-001's promising?safety and tolerability profile, its absence of psychotomimetic and hallucinogenic effects typically seen with traditional psychedelics, and its exciting?potential for advancing depression treatment. Watch the video here: https://lnkd.in/euGdNd6B #neuroscience #TeamDelix

2024 was a year of execution for the Delix Therapeutics team, showcasing our commitment to pioneering meaningful advances in the field of neuroscience. Key highlights include earning a prestigious grant from the United States Department of Defense,?advancing our lead compound, DLX-001,?to patients in the next phases of clinical development, publishing breakthrough research in Science Magazine, and nominating another Development Candidate. As we wrap up a transformative 2024, we’re excited for the opportunities 2025 holds to innovate, grow, and make an impact. #TeamDelix #Innovation #Neuroplastogens

Pranay Srivastava, Ph.D. is an experienced Neuroplasticity Scientist who works?with Delix Therapeutics cutting-edge technology to explore the complexities of synapse function. He shares what he loves most about his role: “I’m endlessly fascinated by the brain’s ability to rewire itself in response to learning, injury, or new experiences. Witnessing the adaptability and resilience of the human brain is truly awe-inspiring. Each day, I feel privileged to contribute to discoveries that have the potential to improve lives. The work challenges me intellectually and continually inspires me with its meaningful real-world impact.” We’re grateful to have Pranay's?extensive skillset and knowledge as we continue to pioneer a new era of #brainhealth. #TeamDelix

As we step into 2025, #TeamDelix sends warm wishes for a happy and healthy new year! In addition to the Sachs Associates 8th Annual Neuroscience Innovation Forum, next week the Delix Therapeutics team will be attending the 2025 J.P. Morgan Healthcare Conference in San Francisco. We look forward to connecting with our investors and partners and diving?into exciting conversations about the future of healthcare, especially the evolving innovations in #neuroscience. #JPM2025

As 2024 winds down, we’re reflecting on some incredible moments at Delix Therapeutics! From our second annual cook-off showcasing culinary talents and friendly competition, to festive fun with ugly sweater contests, gingerbread house building, and great tunes, it's been a season of celebration. We wrapped up the year with an unforgettable party, bringing together our team and families for a night of celebration. These moments highlight the culture we’re building – one rooted in collaboration, creativity, and shared success. Here’s to making 2025 even more memorable!

Join Delix Therapeutics at the Sachs Associates 8th Annual Neuroscience Innovation Forum on Sunday, January 12th. Hear from Delix's Head of Research and Development, Eliseo Salinas MD MSc, as he joins a panel of leading industry experts in a discussion about "Revolutionizing Neuropsychiatric Treatments: Novel Approaches." Learn about the latest breakthroughs in innovative therapies shaping the future of #brainhealth. Delix’s Head of Corporate Strategy, Retsina Meyer, PhD, will also be attending—connect with her to explore the company’s vision for the future. We look forward to seeing you there!? Register here: https://lnkd.in/eqsikY63

Meet Dan Gillie, Principal Scientist at Delix Therapeutics! Dan plays a crucial role in developing medicines for patients suffering from brain and neurological disorders. With a passion for understanding how #neuroplasticity can help address neurodegenerative conditions, Dan is dedicated to finding innovative solutions. We are incredibly grateful for the expertise and commitment he brings to #TeamDelix every day.

At the American College of Neuropsychopharmacology’s 63rd Annual Meeting this week, Delix Therapeutics announced complete?results from our Phase 1 trial evaluating novel #neuroplastogen DLX-001 in healthy volunteers. We also presented preclinical data on DLX-159, our third developmental candidate in our pipeline. We’re proud of our incredible team of scientists who made these achievements possible, as we continue to push the boundaries of #neuroscience and pioneer a new era of #brainhealth. Discover more about our findings: https://lnkd.in/ddayE2BJ.

We’re thrilled to welcome Princely Tamfu, a Research Associate/Lab Operations Manager to Delix Therapeutics! Princely is excited to contribute to #TeamDelix by developing cutting-edge solutions for #CNS conditions. We’re grateful to have his expertise onboard, as we seek to revolutionize #brainhealth and bring safe, fast-acting, and long-lasting #neuroplastogens to patients in need.

We are excited to announce the initiation of our Phase 1b clinical trial evaluating DLX-001, a novel #neuroplastogen, in patients with Major Depressive Disorder (MDD). MDD is a complex and widespread mental health condition that affects over 280 million people globally, including?21 million?in the United States. Despite available treatment options, many patients do not experience a fast and durable?response, highlighting the critical need for new and differentiated treatments.? This trial marks an important advancement in Delix's mission to pioneer cutting-edge #neurotherapeutics that enhance neuroplasticity and deliver transformative outcomes for patients. Discover more about our Phase 1b study: https://lnkd.in/d3EnxP6R.